BCAB Stock Price History and Quote Analysis Insights for Investors
BioAtla, Inc.
Stock Price Today
BioAtla, Inc. (BCAB) stock surged +1.40%, trading at $1.45 on NASDAQ, up from the previous close of $1.43. The stock opened at $1.46, fluctuating between $1.42 and $1.49 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Company Information
| Employees | 65 |
| Beta | 1.02 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
BioAtla, Inc. (NASDAQ: BCAB) stock price is $1.45 in the last trading session. During the trading session, BCAB stock reached the peak price of $1.49 while $1.42 was the lowest point it dropped to. The percentage change in BCAB stock occurred in the recent session was 1.4% while the dollar amount for the price change in BCAB stock was $0.02.
The NASDAQ listed BCAB is part of Biotechnology industry that operates in the broader Healthcare sector. BioAtla, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Eric L. Sievers M.D.
Chief Medical Officer
Ms. Susie Melody
Senior Vice President of HR
Mr. Philippe Martin
Chief Clinical Devel. & Operations
Ms. Monica Sullivan
Senior Vice President of Intellectual Property & Contracts
Dr. Jay M. Short Ph.D.
Co-Founder, Chief Executive Officer & Chairman
Dr. Cathy Chang Ph.D.
Senior Vice President of R&D
Lisa M. Pelton
Accounting Mang.
Dr. Gerhard Frey Ph.D.
Senior Vice President of Technology Devel.
Ms. Sheri Lydick
Senior Vice President of Commercial Strategy
Mr. Richard A. Waldron
Senior Vice President & Chief Financial Officer
Mr. Christian Vasquez
Senior Vice President of Fin. & Sec.
Mr. Christian J. Vasquez
Senior Vice President of Fin., Corporation Controller & Sec.
Mr. Scott Andrew Smith
Chief Executive Officer & Director
BCAB's closing price is 27.19% higher than its 52-week low of $1.14 where as its distance from 52-week high of $4.02 is -63.93%.
Number of BCAB employees currently stands at 65.
Official Website of BCAB is: https://www.bioatla.com
BCAB could be contacted at phone 858 558 0708 and can also be accessed through its website. BCAB operates from 11085 Torreyana Road, San Diego, CA 92121, United States.
BCAB stock volume for the day was 304.99K shares. The average number of BCAB shares traded daily for last 3 months was 1.2M.
The market value of BCAB currently stands at $70.10M with its latest stock price at $1.45 and 48.35M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com